Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the Dose from the safety and tolerability of intravenous Brincidofovir (BCV, SyB V-1901) using multiple ascending doses in subjects with Adenovirus infection.


Clinical Trial Description

This is a Phase IIa, open-label, multiple ascending dose confirmation, multicenter study to evaluate the safety and tolerability of intravenous Brincidofovir (BCV, SyB V-1901) 0.2 mg/kg, 0.3 mg/kg, or 0.4 mg/kg dosed BIW or 0.4 mg/kg dosed QW (Cohorts 1 to 4) in adult and pediatric subjects with AdV viremia. A total of 24 subjects aged 2 months and older will be enrolled: 6 subjects to each Cohort. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04706923
Study type Interventional
Source SymBio Pharmaceuticals
Contact Kohji Shimasaki
Phone +81-3-6684-6616
Email MedInfo@symbiopharma.com
Status Recruiting
Phase Phase 2
Start date August 16, 2021
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04722029 - Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections Phase 1/Phase 2
Completed NCT00711035 - Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) Phase 1/Phase 2
Completed NCT00880789 - Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus Phase 1
Terminated NCT05179057 - Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation Phase 3
Terminated NCT05305040 - Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Phase 2/Phase 3
Completed NCT02087306 - Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection Phase 3
Active, not recruiting NCT03475212 - Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT00590083 - Administration of Virus-Specific Cytotoxic T-Lymphocytes Phase 1
Recruiting NCT03159364 - Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections Phase 1/Phase 2
Recruiting NCT05101213 - Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients Phase 1
Completed NCT01070797 - Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) Phase 1
Active, not recruiting NCT04693637 - Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Phase 2/Phase 3
Withdrawn NCT02276820 - Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A) Phase 1
Recruiting NCT02007356 - A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® Phase 2
Withdrawn NCT02702427 - Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT02851576 - Clinical Grade Adenovirus Specific T Cells for Immunotherapy After Allogeneic Stem Cell Transplantation (CTL-ADV) Phase 1/Phase 2